ID: ALA415726

Max Phase: Preclinical

Molecular Formula: C16H16N2O4

Molecular Weight: 300.31

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  O=C(CCC(=O)Nc1ccc(O)cc1)Nc1ccc(O)cc1

Standard InChI:  InChI=1S/C16H16N2O4/c19-13-5-1-11(2-6-13)17-15(21)9-10-16(22)18-12-3-7-14(20)8-4-12/h1-8,19-20H,9-10H2,(H,17,21)(H,18,22)

Standard InChI Key:  GFMAOCXRFKDDDX-UHFFFAOYSA-N

Associated Targets(Human)

Cyclooxygenase 1258 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 300.31Molecular Weight (Monoisotopic): 300.1110AlogP: 2.46#Rotatable Bonds: 5
Polar Surface Area: 98.66Molecular Species: NEUTRALHBA: 4HBD: 4
#RO5 Violations: 0HBA (Lipinski): 6HBD (Lipinski): 4#RO5 Violations (Lipinski): 0
CX Acidic pKa: 9.16CX Basic pKa: CX LogP: 1.86CX LogD: 1.86
Aromatic Rings: 2Heavy Atoms: 22QED Weighted: 0.64Np Likeness Score: -0.49

References

1. Vennerstrom JL, Holmes TJ..  (1987)  Prostaglandin-H synthase inhibition by malonamides. Ring-opened analogues of phenylbutazone.,  30  (2): [PMID:3100804] [10.1021/jm00385a031]

Source